Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis
Jessica I. Sanchez(The University of Texas MD Anderson Cancer Center), Laura Beretta(The University of Texas MD Anderson Cancer Center), John M. Vierling(Baylor College of Medicine), J. Lee(Baylor College of Medicine), Suet‐Ying Kwan(The University of Texas MD Anderson Cancer Center), Darrel W. Cleere(Methodist Hospital), Peng Wei(Creighton University), Ahmed Elsaiey(Methodist Hospital), Antoine C. Fontillas(The University of Texas MD Anderson Cancer Center), Caren I. Sanchez(The University of Texas MD Anderson Cancer Center), David W. Victor(Methodist Hospital), Tiffany L. Calderone(National Institutes of Health)
Cited by 21
Related Papers
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
|The Lancet. Gastroenterology & hepatology|2022|255